ClinicalTrials.gg
CompletedNCT02221271Updated Apr 12, 2017

Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

A Phase 3 interventional study of NPB-01 in Guillain-Barré Syndrome, sponsored by Nihon Pharmaceutical Co., Ltd. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days.

Patients evaluate the Functional Grade(FG) and Arm Grade(AG) et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.

02

Conditions studied

  • Guillain-Barré Syndrome
03

In context

Guillain-Barre Syndrome

98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.

This study's enrollment of 22 is below the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.

Browse Guillain-Barre Syndrome studies →

Lead sponsor

Nihon Pharmaceutical Co., Ltd is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In principle, patients are able to receive study drug within 2weeks(with limits of 4weeks) from the start of symptoms.
  2. Patients with predominant motor neuropathy and Hughes's Functional Grade(FG) is grade4 or grade5(in this regard, if symptoms is progressive, patients with FG is grade3 involve in this study).
  3. Patients with plasmapheresis, (in prednisolone equivalent, more than 100mg/day) and immune globulin therapy is no operation for this onset.
  4. Patients with greater than or equal to 18 years old at .

Exclusion criteria

Exclusion Criteria:

  1. Patients with history of shock for NPB-01.
  2. Patients with history of for NPB-01.
  3. Patients with history of volatile organic solvent abuse, abnormal porphyrin metabolism, history of pharynx or cutaneous diphtheria, plumbism, tephromyelitis, botulism, hysterical paralysis, toxic neuropathy(nitrofurantoin, dapsone, organophosphorous compound), serious diabetic neuropathy,peripheral neuropathy due to ,impaired peripheral neuropathy except Guillain-Barré syndrome.
  4. Patients with at .
  5. Patients treated with immune globulin at 8 weeks before informed consent.
  6. Patients with IgA deficiency.
  7. Patients with impaired liver function.
  8. Patients with impaired renal function.
  9. Patients with cerebro- or cardiovascular disorders.
  10. Patients with high risk of thromboembolism.
  11. Patients with hemolytic/hemorrhagic anemia.
  12. Patients with decreased cardiac function.
  13. Patients with decreased .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    NPB-01

    Drug: NPB-01

Interventions

06

What researchers measure

Primary outcomes

  1. proportion of patients with more than 1grade improvement in the Hughes functional grading scale(FG) relative to baseline at 4weeks.

    Time frame: Baseline,4weeks

Secondary outcomes

  1. days required for 1 grade improvement of the Hughes functional grading scale(FG)

    Time frame: Baseline,1,2,3,4,5,6,7,8,9,10,11,12 weeks

  2. days required for 2 grade improvement of the Hughes functional grading scale(FG)

    Time frame: Baseline,1,2,3,4,5,6,7,8,9,10,11,12 weeks

  3. changes in Hughes functional grading scale(FG)

    Time frame: Baseline,1,2,3,4,5,6,7,8,9,10,11,12 weeks

  4. proportion of patients with more than 1 grade improvement in the Arm Grade(AG) relative to baseline at 4weeks.

    Time frame: Baseline,4weeks

  5. days required for 1 grade improvement of the Arm Grade(AG)

    Time frame: Baseline,1,2,3,4,5,6,7,8,9,10,11,12 weeks

  6. days required for 2 grade improvement of the Arm Grade(AG)

    Time frame: Baseline,1,2,3,4,5,6,7,8,9,10,11,12 weeks

  7. changes in Arm Grade(AG)

    Time frame: Baseline,1,2,3,4,5,6,7,8,9,10,11,12 weeks

  8. changes in manual muscle testing(MMT)

    Time frame: Baseline,1,2,3,4,8,12 weeks

  9. changes in grip strength

    Time frame: Baseline,1,2,3,4,8,12 weeks

  10. changes in activity of daily living(ADL)

    Time frame: Baseline,1,2,3,4,8,12 weeks

  11. changes in electrophysiological findings

    Time frame: Baseline,4,12 weeks

07

Study locations

1 site
  • Nihon Pharmaceutical Co., Ltd
    Osaka, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Aug 2015, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2014
First posted
Aug 20, 2014
StartActual
Oct 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02221271
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Aug 20, 2014
Start date
Oct 2014
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Apr 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion